SuperworthBioCardia EV/EBIT BCDA
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2014.
- Today, Oct 23, 2026
- n/m
- an operating loss
- Last meaningful
- 158×
- Apr 2016
- Peer median
- 8.2×
BioCardia has no meaningful EV/EBIT today: it made an operating loss of $7.4M over the last twelve months.
It was last meaningful in Apr 2016, at 158×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2016 | 158× | 119× | 178× |
| 2015 | 143× | 95.3× | 442× |
| 2014 | 402× | 322× | 499× |
Against its peers
Companies in Healthcare nearest BioCardia's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| BCDABioCardia | n/m |
| NEPHNephros | 20.5× |
| ATNMActinium Pharmaceuticals | 1.2× |
| APTAlpha Pro Tech | 8.2× |
| SPROSpero Therapeutics | 2.1× |
| LFVNLifevantage | 9.6× |
| ICCCImmucell | 14.2× |
| KEQUKewaunee Scientific | 7.2× |
| Peer median | 8.2× |
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on BioCardia
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.